TC Medical(SH:600763) Sou Hu Cai Jing·2026-01-20 11:27Core Viewpoint - Tongce Medical (600763) experienced a decline in stock price, closing at 44.3 yuan on January 20, 2026, with a turnover rate of 2.26% and a trading volume of 101,000 hands, resulting in a transaction amount of 449 million yuan [1] Group 1: Financial Performance - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, an increase of 2.56% year-on-year [2] - The net profit attributable to shareholders was 514 million yuan, up 3.16% year-on-year, while the net profit excluding non-recurring items was 509 million yuan, reflecting a 3.09% increase year-on-year [2] - In Q3 2025, the company achieved a single-quarter main revenue of 842 million yuan, a year-on-year increase of 2.34%, and a net profit attributable to shareholders of 192 million yuan, up 2.31% year-on-year [2] - The company's debt ratio stands at 25.1%, with investment income of 41.22 million yuan and financial expenses of 31.93 million yuan, resulting in a gross profit margin of 41.69% [2] Group 2: Market Activity - On January 20, 2026, the net outflow of main funds was 59.49 million yuan, accounting for 13.24% of the total transaction amount, while retail investors saw a net inflow of 39.88 million yuan, representing 8.87% of the total transaction amount [1] - Over the past 90 days, seven institutions have provided ratings for the stock, with four buy ratings and three hold ratings, and the average target price set by institutions is 5.288 billion yuan [2]